Plus Therapeutics (PSTV) AI Stock Analysis

• Market Cap: $13.38M
• Dividend Yield: N/A
• Average Volume (3M): 17.96M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.96
• Revenue Growth: 18.54%
• EPS Growth: 50.37%
• Country: US
• Employees: 21
• Sector: Healthcare
• Sector Strength: 64
• Industry: Biotechnology
• EPS (TTM): -2.06
• Shares Outstanding: 16,999,626
• 10 Day Avg. Volume: 3,405,549
• 30 Day Avg. Volume: 17,955,920
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.79
• Price to Cash Flow (P/CF): -0.50
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $6.17
• Price Target Upside: 529.59% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3

Plus Therapeutics faces significant financial challenges with persistent losses, negative equity, and cash flow issues, resulting in a low overall score. While technical indicators and valuation suggest potential caution, strategic financing moves and positive earnings call insights offer some optimism for future growth. The company's ability to leverage clinical successes and financial strategies will be crucial for improving its stock performance.

Positive Factors

Clinical Trials

The P2b ReSPECT-GBM study is progressing with enrollment expected to complete soon, demonstrating targeted radiation exposure in initial imaging data.

Financing

Plus Therapeutics has secured financing to extend its operational runway with a $15.0M equity financing and a $50M stock purchase agreement.

Negative Factors

Adverse Event

Stock weakness following the data presentation comes from an overreaction to a reported dose-limiting toxicity (hemiplegia).

Stock Price Target

Lowering the 12-month price target to $5.50 per share from $8.00 to account for the increased number of outstanding shares and warrants.

Plus Therapeutics Business Overview & Revenue Model

Company Description

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.

How the Company Makes Money

Plus Therapeutics generates revenue primarily through funding and partnerships related to its research and development activities. The company seeks collaborations with research institutions and healthcare organizations to advance its clinical trials and bring its therapies to market. Additionally, Plus Therapeutics may receive grant funding and milestone payments contingent on the achievement of certain clinical or regulatory objectives. As a clinical-stage company, its revenue model heavily relies on successfully progressing through clinical trials and obtaining regulatory approval, which would eventually allow it to commercialize its therapies and generate sales revenues.

Plus Therapeutics Financial Statement Overview

Summary

Plus Therapeutics faces significant financial challenges, with declining revenue and persistent losses impacting profitability. The negative equity and high leverage pose substantial risks, while the negative cash flows highlight liquidity issues. Strategic improvements in revenue generation and cost management are crucial for financial stabilization.

Income Statement

Plus Therapeutics shows a significant decline in revenue with a negative revenue growth rate from 2023 to TTM. The gross and net profit margins are negative, indicating ongoing losses. EBIT and EBITDA margins are also negative, reflecting operational inefficiencies and high costs. The company’s revenue has been inconsistent, leading to a poor income statement rating.

Balance Sheet

The balance sheet reveals a negative stockholders' equity, indicating financial instability. The debt-to-equity ratio is not applicable due to negative equity, suggesting excessive leverage. ROE cannot be calculated due to negative equity, and the equity ratio also shows a negative number. Overall, the balance sheet reflects significant financial risk and a weak capital structure.

Cash Flow

Operating and free cash flows are negative, indicating poor cash generation. The free cash flow growth rate is slightly improved from 2023 to TTM, but still negative. The operating cash flow to net income ratio suggests inefficiencies in converting income to cash. Overall, the cash flow analysis presents a challenging liquidity position.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
4.27M	4.91M	224.00K	0.00	303.00K	7.00M
	Gross Profit
1.13M	-4.78M	-488.00K	-66.00K	-2.40M	1.63M
	EBIT
-14.65M	-13.32M	-19.71M	-12.49M	-9.58M	-3.66M
	EBITDA
-11.90M	-12.69M	-18.85M	-12.49M	-6.76M	-987.00K
	Net Income Common Stockholders
-12.88M	-13.32M	-20.84M	-14.33M	-9.35M	-12.74M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
22.68M	8.55M	18.12M	18.40M	8.35M	17.55M
	Total Assets
35.45M	11.39M	23.87M	21.98M	12.11M	23.23M
	Total Debt
4.93M	4.18M	5.64M	6.99M	7.00M	11.85M
	Net Debt
-17.75M	-4.37M	-12.47M	-11.41M	-1.35M	-5.70M
	Total Liabilities
22.71M	12.74M	17.42M	11.14M	9.07M	22.07M
	Stockholders Equity
12.74M	-1.35M	6.45M	10.84M	3.03M	1.16M
Cash Flow		Free Cash Flow
-11.95M	-13.01M	-13.48M	-10.42M	-8.93M	-5.97M
	Operating Cash Flow
-11.22M	-12.85M	-12.97M	-10.28M	-8.43M	-5.91M
	Investing Cash Flow
-4.22M	-160.00K	-759.00K	-82.00K	-493.00K	5.57M
	Financing Cash Flow
5.66M	3.44M	13.45M	20.42M	-319.00K	12.63M

Plus Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.98
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PSTV, the sentiment is Positive. The current price of 0.98 is above the 20-day moving average (MA) of 0.88, above the 50-day MA of 0.96, and below the 200-day MA of 1.28, indicating a neutral trend. The MACD of -0.07 indicates Negative momentum. The RSI at 54.07 is Neutral, neither overbought nor oversold. The STOCH value of 41.87 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PSTV.

Plus Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$5.20B	3.26	-40.34%	2.93%	17.68%	1.94%
PSTV	45 Neutral	$13.38M	―	249.03%	―	18.54%	50.37%
ADXN	45 Neutral	$11.18M	1.11	-85.36%	―	-70.05%	―
AFMD	42 Neutral	$11.25M	―	-151.46%	―	-95.23%	-325.89%
NERV	37 Underperform	$11.96M	9.36	>-0.01%	―	―	―
GOVX	32 Underperform	$14.12M	―	-462.31%	―	―	56.88%

Plus Therapeutics Corporate Events

Plus Therapeutics Appoints Kyle Guse to Board

On April 18, 2025, Plus Therapeutics, Inc. appointed Mr. Kyle Guse to its Board of Directors, filling the vacancy left by Mr. Greg Petersen’s resignation. Mr. Guse, who has extensive experience in finance, corporate governance, and law, will also serve on the Audit and Compensation Committees, and as Chairman of the Audit Committee. His appointment is seen as a strategic move to strengthen the company’s governance and financial oversight.

Spark’s Take on PSTV Stock

According to Spark, TipRanks’ AI Analyst, PSTV is a Underperform.

Plus Therapeutics faces significant financial challenges with consistent losses, negative equity, and cash flow difficulties. The promising clinical trials and successful financing offer some forward-looking optimism, yet the valuation remains a concern due to no earnings and lack of dividends. While technical indicators show neutral momentum, the company’s financial position requires strategic improvement.

To see Spark’s full report on PSTV stock, click here.

Plus Therapeutics Secures $3.7M in Convertible Notes Deal

On February 13, 2025, Plus Therapeutics entered into a Securities Purchase and Exchange Agreement with existing accredited investors, issuing secured convertible promissory notes and common stock purchase warrants totaling approximately $3.7 million. These financial instruments are secured by most of the company’s assets and come with various conversion options and covenants, indicating a strategic effort to manage financial obligations and leverage future financing opportunities. Additionally, the company announced a $2.0 million advance from the Cancer Prevention and Research Institute of Texas, which is part of a larger $17.6 million grant, highlighting a continued partnership in cancer research funding.